The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.
Description: progression of disease within 2 months from registration according to RECIST criteria, and death for any cause within 2 months from registrationMeasure: number of patients alive and without disease progression Time: 2 months
Description: Response assessed per patients at weeks 8,16,24,32,40 and every 3 months thereafter, using RECIST criteriaMeasure: response rate Time: up to 40 weeks
Description: worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 3) per patientMeasure: worst grade toxicity per patient Time: every 2 weeks for up to 6 months
Description: exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression statusMeasure: gene expression on tumor tissue Time: one year
Single Group Assignment
There is one SNP
exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression status. --- P13K ---